The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...

Abnormalities of the vitreoretinal interface may contribute to important retinal pathologies such as diabetic ... treatment option currently available is vitrectomy. Pharmacologic treatment ...

"There is a significant unmet medical need for patients suffering from diabetic retinopathy, a leading cause of blindness in the US, and current treatment options consist mainly of invasive ...

This is a higher dose, longer-acting form of the drug, and it’s used to treat wet AMD, diabetic retinopathy ... talk with your doctor about your treatment options. Eylea’s most common side ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

These tools particularly excel at identifying conditions like diabetic retinopathy ... promise even more precise diagnostic tools and treatment options, potentially revolutionizing how we approach ...